Arrowhead Is A Buy On REDEMPLO™ Approval And Strong Cash Runway (NASDAQ:ARWR)

Core Insights - Arrowhead Pharmaceuticals, Inc. achieved a significant milestone with the approval of their lead drug candidate REDEMPLO™ (formerly known as Plozasiran) on November 18th [1] Company Summary - REDEMPLO™ is positioned as a transformative drug for Arrowhead Pharmaceuticals, marking a pivotal moment in the company's development and potential market impact [1] Industry Context - The approval of REDEMPLO™ reflects ongoing advancements in the pharmaceutical industry, particularly in the area of innovative drug development [1]